Evaluation of 0.25% AGN-229666 ophthalmic solution compared to vehicle or olopatadine in the conjunctival allergen challenge (CAC) model of allergic conjunctivitis
Phase of Trial: Phase III
Latest Information Update: 04 Feb 2019
At a glance
- Drugs AGN 229666 (Primary) ; Olopatadine
- Indications Allergic conjunctivitis
- Focus Therapeutic Use
- Sponsors Senju Pharmaceutical
- 01 Feb 2019 Status changed from active, no longer recruiting to completed.
- 31 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 05 Sep 2017 Status changed from not yet recruiting to recruiting.